Company profile: Q'Apel Medical
1.1 - Company Overview
Company description
- Provider of neurovascular access and stroke intervention devices, including the Walrus Balloon Catheter System for mechanical thrombectomy with a large inner diameter and high trackability; the Hippo Advanced Aspiration System for rapid clot removal with visible clot engagement and flexible navigation; and the Armadillo Neurovascular Access System with dual-mode radial and femoral adaptability, trackability, and support for complex anatomy.
Products and services
- Armadillo Neurovascular Access System: Dual-mode adaptable neurovascular access catheter engineered for radial and femoral artery access, delivering trackability and support for complex neurovascular anatomy
- Hippo Advanced Aspiration System: Stroke-focused aspiration system developed for rapid clot removal in stroke procedures, featuring visible clot engagement and a flexible navigation system
- Walrus Balloon Catheter System: Mechanical thrombectomy-optimized balloon guide catheter for stroke patients, featuring a large inner diameter and high trackability for mechanical thrombectomy procedures
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Q'Apel Medical
Alcyone Therapeutics
HQ: United States
Website
- Description: Provider of precision CNS genetic therapies and delivery technologies, including Falcon Precision Delivery System for precise intra-CSF drug delivery; ThecaFlex DRx System, an implantable system for direct intrathecal CSF access designed for safer, long-term drug administration; ACTX-101 gene therapy for Rett syndrome using X-reactivation; and miREX to reactivate silenced healthy X chromosomes for X-linked dominant mutations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alcyone Therapeutics company profile →
Kineta
HQ: United States
Website
- Description: Provider of biotechnology drug discovery focused on diseases caused by protein misfolding, offering immunotherapies such as KVA12123, a VISTA-blocking agent in Phase 1/2 trials as monotherapy and with pembrolizumab, and an anti-CD27 agonist mAb to activate T and NK cells and address exhausted T cells in the tumor microenvironment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kineta company profile →
Neumora
HQ: United States
Website
- Description: Provider of clinical-stage investigational therapies for brain diseases, conducting trials to evaluate new treatments. Portfolio includes navacaprant, an investigational oral Phase 3 medication for major depressive disorder that modulates dopamine and reward processing pathways, plus NMRA-NLRP3 and NMRA-GCASE programs for neurodegenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neumora company profile →
Neuronetics
HQ: United States
Website
- Description: Provider of non-drug, non-invasive TMS therapies for mental health, including NeuroStar Advanced Therapy for major depressive disorder using precise magnetic stimulation, supported by the TrakStar HIPAA-compliant practice management system and features like MT Assist and Contact Sensing for accurate dosing and real-time treatment feedback.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neuronetics company profile →
ArmaGen
HQ: United States
Website
- Description: Provider of therapies and siRNA delivery technologies that penetrate the blood-brain barrier to treat neurological complications of diseases, including lysosomal storage disorders (LSDs), Alzheimer's and Parkinson's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArmaGen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Q'Apel Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Q'Apel Medical
2.2 - Growth funds investing in similar companies to Q'Apel Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Q'Apel Medical
4.2 - Public trading comparable groups for Q'Apel Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →